Lupin Expands European Ophthalmology Footprint with VISUfarma Acquisition
Event summary
- Lupin completed the acquisition of VISUfarma on April 2, 2026, for an undisclosed amount.
- The deal adds over 60 branded ophthalmology products to Lupin's portfolio.
- VISUfarma generated €53 million in revenue in 2025 across key European markets.
- Lupin gains a commercial footprint in Italy, UK, Spain, Germany, and France.
The big picture
The acquisition aligns with Lupin's strategy to strengthen its specialty care portfolio amid growing global demand for eye care solutions. The deal underscores the trend of pharmaceutical companies expanding into high-growth therapeutic areas through targeted acquisitions. Lupin's move also highlights the increasing importance of European markets for global pharma players seeking to diversify beyond the U.S. and emerging markets.
What we're watching
- Integration Challenges
- How Lupin will manage the integration of VISUfarma's commercial teams and product portfolios.
- Market Penetration
- Whether Lupin can leverage VISUfarma's local market insight to accelerate growth in Europe.
- Competitive Response
- The pace at which competitors react to Lupin's expanded ophthalmology presence.
Related topics